Format

Send to

Choose Destination
Chem Commun (Camb). 2015 Mar 7;51(19):4055-8. doi: 10.1039/c4cc10265g.

Development of an enzymatic pretargeting strategy for dual-modality imaging.

Author information

1
CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK. bart.cornelissen@oncology.ox.ac.uk.

Abstract

A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.

PMID:
25660394
DOI:
10.1039/c4cc10265g
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Royal Society of Chemistry
Loading ...
Support Center